(IN BRIEF) Roche reported groundbreaking phase III IMvigor011 results showing that Tecentriq (atezolizumab) significantly improved overall and disease-free survival in muscle-invasive bladder cancer using a ctDNA-guided treatment approach. Patients receiving Tecentriq experienced a 41% lower risk of death and a … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged adjuvant therapy, atezolizumab, bladder cancer, Cancer Immunotherapy, ctDNA, disease-free survival, ESMO Congress 2025, IMvigor011, Levi Garraway, molecular residual disease, MRD testing, muscle-invasive bladder cancer, Natera, oncology research, precision oncology, Roche, Roche Advances Personalized Oncology with Positive Phase III Tecentriq Results in ctDNA-Directed Bladder Cancer Treatment, Roche’s Tecentriq Shows 41% Survival Benefit in Landmark ctDNA-Guided Bladder Cancer Study, Signatera, survival benefit, TECENTRIQ, Thomas Powles
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?